Alcon-STAAR Surgical Merger Advances as Hart-Scott-Rodino Waiting Period Expires
核心洞察
The Hart-Scott-Rodino antitrust waiting period for Alcon's $1.5 billion acquisition of STAAR Surgical (搜索) expired on September 29, 2025, marking a key regulatory milestone.
Under the merger agreement, Alcon will acquire all outstanding STAAR shares for $28 per share in cash, representing a 59% premium to STAAR's 90-day volume-weighted average price.
STAAR's 45-day "window shop" period has expired without any competing acquisition proposals, despite opposition from shareholder Broadwood Partners (搜索).
Alcon's $1.5 billion acquisition of STAAR Surgical (搜索) has cleared a significant regulatory hurdle with the expiration of the Hart-Scott-Rodino (HSR) antitrust waiting period on September 29, 2025. The milestone brings the eye care industry consolidation one step closer to completion, pending stockholder approval and other customary closing conditions.
Under the merger agreement announced in August 2025, Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash. This represents approximately a 59% premium to STAAR's 90-day volume-weighted average price and a 51% premium to the closing price on August 4, 2025, the day prior to the transaction announcement.
Strategic Rationale and Market Impact
"Together with STAAR, Alcon will be able to offer treatment options across the full spectrum of myopia (搜索), reinforcing our commitment to addressing the most significant needs in eye care," said David Endicott, CEO of Alcon.
The acquisition centers on STAAR's EVO family of Implantable Collamer Lenses (ICLs), which provide vision correction for patients with moderate to high myopia (搜索) with or without astigmatism (搜索). These implantable lenses address vision correction needs through a minimally invasive, reversible procedure that does not remove corneal tissue. The EVO ICLs are implanted between the iris and the natural crystalline lens.
STAAR has established itself as the global leader in implantable phakic intraocular lenses, having sold more than 3 million ICLs in over 75 countries since dedicating itself to this technology for 30 years.
Window Shopping Period Concludes Without Competing Bids
STAAR Surgical (搜索) confirmed the expiration of the 45-day "window shop" period under the merger agreement terms, during which the company could have accepted competing acquisition proposals with only a 1% termination fee. Following this period, any termination would require a 3% fee payable to Alcon.
Stephen Farrell, CEO of STAAR, addressed the lack of competing offers: "The company has not received any competing proposal since media reports of takeover interest in STAAR first surfaced in July 2024, nor since the Alcon merger agreement was announced."
This statement came in response to opposition from Broadwood Partners (搜索), a significant shareholder that has repeatedly claimed other parties were interested in acquiring STAAR. Despite Broadwood's assertions of contact with possible strategic and financial parties, no competing proposal materialized during the window shopping period.
Shareholder Opposition and Board Response
Broadwood Partners (搜索) has provided significant input on STAAR's governance, having recommended three of the Board's current six members and voting for all directors at STAAR's 2025 Annual Meeting. However, the Board unanimously approved the Alcon agreement after extensive consideration of Broadwood's opposition and its fiduciary responsibility to all stockholders.
"Collectively, the Board and management team understand the market risks, trends, and opportunities better than Broadwood, and Broadwood's opposition to the transaction is unfounded," Farrell stated.
The company emphasized that Broadwood is asking stockholders to "forfeit the all-cash, premium value provided by the Alcon merger agreement and instead underwrite the significant risks inherent in STAAR as a standalone company." STAAR warned that failure of the acquisition could lead to "significant value destruction."
Transaction Timeline and Approval Process
STAAR will hold a virtual Special Meeting of Stockholders on October 23 at 8:30 a.m. Pacific Time to vote on the merger proposal. Stockholders of record as of September 12, 2025, are entitled to vote, with the Board unanimously recommending approval.
According to BTIG (搜索), a global financial services firm, "concentrated ownership is a bit of a wildcard, and the proxy confirms that its largest shareholder was not supportive of the transaction for a period of time and has not said publicly which way they may vote." However, BTIG believes STAAR will secure sufficient votes from other shareholders to proceed with the merger.
The transaction is anticipated to close within six to 12 months of the initial merger agreement announcement, subject to customary closing conditions including regulatory approval and stockholder approval.
Financial and Strategic Benefits
"With the expiration of HSR, we are one step closer toward completing this value-maximizing transaction for STAAR stockholders," said Farrell. "In addition to providing our stockholders with compelling, certain, and premium cash value, Alcon's resources will enable us to accelerate adoption of EVO ICL (搜索) by surgeons and patients."
The merger combines Alcon's global reach and resources with STAAR's specialized ICL technology, positioning the combined entity to address the growing myopia (搜索) market more comprehensively. Alcon's established presence in over 140 countries, serving more than 260 million people annually, provides a platform for expanding EVO ICL (搜索) adoption.
Morgan Stanley (搜索) & Co. LLC serves as financial advisor to Alcon, with Gibson, Dunn & Crutcher LLP as legal advisor. Citi (搜索) serves as exclusive financial advisor to STAAR, with Wachtell, Lipton, Rosen & Katz as legal advisor.